Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study

Hira S Mian, Tanya Wildes, Ravi Vij, Ajay Major, Mark A Fiala

Blood (2022) 140 (Supplement 1): 423–424.

https://doi.org/10.1182/blood-2022-158277

Published: 2022

Journal Articles

A Novel Serum Free Light Chain Metric Provides Greater Diagnostic Specificity and Robustness to Variation in Renal Function

Vahid Azimi, Michael J Slade, Mark A Fiala, Julie M Fortier, Keith E Stockerl-Goldstein, John L Frater, Jonathan R Brestoff, Ronald Jackups, Jr., Mark A Zaydman

Blood (2022) 140 (Supplement 1): 7160–7161.

https://doi.org/10.1182/blood-2022-167588

Published: 2022

Journal Articles

Association between Bone Marrow Immune Microenvironment Following Autologous Stem Cell Transplant and Duration of Response for Multiple Myeloma

Tianjiao Wang, Mark A Fiala, Julie M Fortier, Ruiyang Liu, Reyka G. Jayasinghe, Ravi Vij, Li Ding

Blood (2022) 140 (Supplement 1): 7066–7067.

https://doi.org/10.1182/blood-2022-169716

Published: 2022

Journal Articles

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2022) 140 (Supplement 1): 4376–4377.

https://doi.org/10.1182/blood-2022-155582

Published: 2022

Journal Articles

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Scott R. Goldsmith, Fahrettin Covut, Mark A. Fiala, Elizabeth Bradtke, Ayan Gasanli, Brandon Christen, Jonathan A. Pachter, Zhifu Xiang, Zahid Iqbal, Nathan Moore, Uchenna Ofoma, Bijal Parikh, Erik Dubberke, John F. DiPersio

Blood (2022) 140 (Supplement 1): 11185–11186.

https://doi.org/10.1182/blood-2022-157605

Published: 2022

Journal Articles

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Jacob Edmisson, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Jingyu Xiang, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij

Blood (2022) 140 (Supplement 1): 4295–4296.

https://doi.org/10.1182/blood-2022-169367

Published: 2022

Journal Articles

Needle in a Haystack: A Pilot Study Combining Single-Cell Multiomics with Clinical NGS-MRD Sequencing to Search for Circulating Clonotypic Dedifferentiated Myeloma Cells

Scott R. Goldsmith, Reyka G. Jayasinghe, Jonathan Adam Scolnick, Jaren Sia, Mark A Fiala, Michael J Slade, Tianjiao Wang, Li Ding, Ravi Vij

Blood (2022) 140 (Supplement 1): 9945–9946.

https://doi.org/10.1182/blood-2022-169604

Published: 2022

Journal Articles

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Kari Wilson, Mark A. Schroeder, Keith E Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo

Blood (2022) 140 (Supplement 1): 8550–8551.

https://doi.org/10.1182/blood-2022-166736

Published: 2022

Journal Articles

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Kinan Alhallak, Amanda Jeske, Pilar De La Puente, Jennifer Sun, Mark A. Fiala, Feda Azab, Barbara Muz, Ilyas Sahin, Ravi Vij, John F. DiPersio, Abdel Kareem Azab

Blood (2021) 138 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2021-153832

Published: 2021

Journal Articles

Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Blood (2021) 138 (Supplement 1): 2691.

https://doi.org/10.1182/blood-2021-154081

Published: 2021

Journal Articles

Financial Toxicity Among Patients with Multiple Myeloma

Alice Silberstein, Mark A. Fiala, Sarah Kelley, Mark A. Schroeder, Keith E. Stockerl-Goldstein, Ravi Vij

Blood (2021) 138 (Supplement 1): 4027.

https://doi.org/10.1182/blood-2021-153653

Published: 2021

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma

Kristen M. Sanfilippo, MD MPHS, Mark A Fiala, MSW, Harsha Tathireddy, MD, Dan Feinberg, Ravi Vij, MD MBA, Brian F. Gage, MD MSc

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142762

Published: 2020

Journal Articles

A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Andrew Jay Portuguese, MD, Mark A Fiala, MSW, Tanya M. Wildes, MD MSCI, Ravi Vij, MBBS, Brea Lipe, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134154

Published: 2020

Journal Articles

Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study

Owais Mian, BHSc, Martine Puts, PhD RN, Arleigh McCurdy, MD BSc, Tanya M. Wildes, MD MSCI, Mark A Fiala, MSW, Matthew Kang, MDFRCPC, Mary Salib, MD, Shabbir Alibhai, MD MSc, Hira S Mian, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-139008

Published: 2020

Journal Articles

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142205

Published: 2020

Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 602.

https://doi.org/10.1182/blood-2019-130644

Published: 2019

Journal Articles

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Tianjiao Wang, BA, Hua Sun, PhD, Daniel Cui Zhou, BA, Ruiyang Liu, BS, Lijun Yao, MS, Mark A. Fiala, MSW, Daniel R. Kohnen, MBA, Julie O'Neal, PhD, Michael P. Rettig, PhD, Jared S Fowles, PhD, Stephen T. Oh, MD, Reyka G Jayasinghe, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD, Li Ding, PhD

Blood (2019) 134 (Supplement_1): 364.

https://doi.org/10.1182/blood-2019-131361

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

NARROW

Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study

A Novel Serum Free Light Chain Metric Provides Greater Diagnostic Specificity and Robustness to Variation in Renal Function

Association between Bone Marrow Immune Microenvironment Following Autologous Stem Cell Transplant and Duration of Response for Multiple Myeloma

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Needle in a Haystack: A Pilot Study Combining Single-Cell Multiomics with Clinical NGS-MRD Sequencing to Search for Circulating Clonotypic Dedifferentiated Myeloma Cells

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Financial Toxicity Among Patients with Multiple Myeloma

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma

A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome

Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only